American Heart Journal
Volume 141, Issue 6 , Pages 899-907 , June 2001

Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: Results of a meta-analysis

Received 21 July 2000 ,Accepted 10 October 2000.

References 

  1. Packer M, Bristow MR, Cohn JN, et al.  Effect of carvedilol on morbidity and mortality in chronic heart failure. N Engl J Med. 1996;334:1349–1355
  2. CIBIS-II Investigators and Committees . The Cardiac Insufficiency Bisoprolol Study-II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13
  3. MERIT-HF Study Group . Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–2007
  4. Domanski MJ, BEST Investigators . Beta-blocker Evaluation of Survival Trial (BEST). J Am Coll Cardiol. 2000;35:202
  5. Xamoterol in Severe Heart Failure Study Group . Xamoterol in severe heart failure. Lancet. 1990;336:1–6
  6. Willette RN, Aiyar N, Yue TL, et al.  In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats. J Pharmacol Exp Ther. 1999;389:48–53
  7. Packer M. Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog Cardiovasc Dis. 1998;41:39–52
  8. Gilbert EM, Abraham WT, Olsen S, et al.  Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996;94:2817–2825
  9. Flesch M, Ettelbrueck S, Rosenkranz S, et al.  Differential effects of carvedilol and metoprolol on β-adrenergic signalling in cardiac myocytes. Circulation. 1999;100(1 Suppl):I202
  10. Dandona P, Karne R, Ghanim H, et al.  Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation. 2000;101:122–124
  11. Ohlstein EH, Arleth AJ, Storer B, et al.  Carvedilol inhibits endothelin-1 biosynthesis in cultured human coronary artery endothelial cells. J Mol Cell Cardiol. 1998;30:167–173
  12. Newton GE, Parker JD. Acute effects of β1-selective and nonselective β-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Circulation. 1996;94:353–358
  13. Du XJ, Autelitano DJ, Dilley RJ, et al.  β2-Adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis. Circulation. 2000;101:71–77
  14. Grupp IL, Lorenz JN, Walsh RA, et al.  Overexpression of alpha1β-adrenergic receptor induces left ventricular dysfunction in the absence of hypertrophy. Am J Physiol. 1998;275:H1338–H1350
  15. Meredith IT, Broughton A, Jennings GL, et al.  Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med. 1991;325:618–624
  16. Kaddoura S, Firth JD, Boheler KR, et al.  Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo: acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist. Circulation. 1996;93:2068–2079
  17. Qin F, Shite J, Liand C-S. Reduction of oxidative stress by Trolox and superoxide dismutase abolishes norepinephrine-induced myocyte apoptosis and β-adrenergic receptor down-regulation in ferrets [abstract]. J Am Coll Cardiol. 2000;35:168A–169A
  18. Hall SA, Cigarroa CG, Marcoux L, et al.  Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol. 1995;25:1154–1161
  19. Eichhorn EJ, Heesch CM, Barnett JH, et al.  Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 1994;24:1310–1320
  20. Follman D, Elliott P, Suh I, et al.  Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol. 1992;45:769–773
  21. Bristow M, Gilbert EM, Abraham WT, et al.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996;94:2807–2816
  22. Packer M, Colucci WS, Sackner-Bernstein JD, et al.  Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate-to-severe heart failure. Circulation. 1996;94:2793–2799
  23. Colucci WS, Packer M, Bristow MR, et al.  Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation. 1996;94:2800–2806
  24. Cohn JN, Fowler MB, Bristow MB, et al.  Safety and efficacy of carvedilol in severe heart failure. J Card Fail. 1997;3:173–179
  25. Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res. 1993;2:121–145
  26. Berkey CS, Hoaglin DC, Mosteller GA. A random-effects regression model for meta-analysis. Stat Med. 1995;14:395–411
  27. Berlin JA, Laird NM, Sacks HS, et al.  A comparison of statistical methods for combining event rates from clinical trials. Stat Med. 1989;8:141–151
  28. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials. 1986;7:177–188
  29. Egger M, Davey Smoth G, Schneider M, et al.  Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634
  30. Bucher HC, Guyatt GH, Griffith LE, et al.  The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683–691
  31. Woodley SL, Gilbert EM, Anderson JL, et al.  Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation. 1991;84:2426–2441
  32. Bristow MR, O’Connell JB, Gilbert EM, et al.  Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation. 1994;89:1632–1642
  33. Metra M, Nardi M, Giubbini R, et al.  Effects of short- and long-term carvedilol administration on rest and hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994;24:1678–1687
  34. Olsen SL, Gilbert EM, Renlund DG, et al.  Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995;25:1225–1231
  35. Krum H, Sackner-Bernstein JD, Goldsmith RL, et al.  Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 1995;92:1499–1506
  36. Australia-New Zealand Heart Failure Research Collaborative Group . Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet. 1997;349:375–380
  37. Guazzi M, Agostoni P, Matturri M, et al.  Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol. Am Heart J. 1999;138:460–467
  38. Engelmeier RS, O’Connell JB, Walsh R, et al.  Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation. 1985;72:536–546
  39. Waagstein F, Bristow MR, Swedberg K, et al.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993;342:1441–1446
  40. Fisher ML, Gottlieb SS, Plotnick GD, et al.  Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol. 1994;23:943–950
  41. Goldstein S, Kennedy HL, Hall C, et al.  Metoprolol CR/XL in patients with heart failure: a pilot study examining the tolerability, safety, and effect on left ventricular ejection fraction. Am Heart J. 1999;138:1158–1165
  42. The RESOLVD Investigators . Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy. The Randomized Evaluation of Strategies for Left Ventricular Pilot Study. Circulation. 2000;101:378–384
  43. Sanderson JE, Chan SK, Yu CM, et al.  Beta blockers in heart failure: a comparison of a vasodilating beta blocker with metoprolol. Heart. 1998;79:86–92
  44. DiLenarda A, Sabbadini G, Salvatore L, et al.  Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. J Am Coll Cardiol. 1999;33:1926–1934
  45. Metra M, Modena M, Giubbini R, et al. Differential effects of beta-blockers in patients with heart failure. A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation (in press).
  46. Kukin ML, Kalman J, Charney RH, et al.  Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation. 1999;99:2645–2651
  47. Sanderson JE, Chan SKW, Yip G, et al.  Beta-blockade in heart failure. A comparison of carvedilol with metoprolol. J Am Coll Cardiol. 1999;34:1522–1528
  48. Sandberg A, Blomqvist I, Jonsson UE, et al.  Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: a comparison with conventional tablets. Eur J Clin Pharmacol. 1988;33(Suppl):S9–S14
  49. Luecker P, Moore G, Wieselgren I, et al.  Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses. J Clin Pharmacol. 1990;30:S17–S27
  50. Bristow MR, Anderson FL, Port JD, et al.  Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation. 1991;84:1024–1039
  51. Bohm M, Gierschik P, Jakobs KH, et al.  Increase of Gi alpha in human hearts with dilated but not ischemic cardiomyopathy. Circulation. 1990;82:1249–1265
  52. Captopril-Digoxin Multicenter Research Group . Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA. 1998;259:539–544
  53. Cohn JN, Johnson G, Ziesche S, et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303–310
  54. Cintron G, Johnson G, Francis G, et al.  Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure: the V-HeFT VA Cooperative Studies Group. Circulation. 1993;87(6 Suppl):17–23
  55. Antonopoulos GV, Lao J, Konstam MA, et al.  Are drug-induced changes in left ventricular ejection fraction or volumes adequate surrogates for long-term natural history outcomes in heart failure [abstract]?. Circulation. 1999;100(1 Suppl):I296
  56. Francis GS, Cohn JN. Heart failure: mechanisms of cardiac and vascular dysfunction and the rationale for pharmacologic intervention. FASEB J. 1990;4:3068–3075
  57. Digitalis Investigation Group . The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;335:1107–1114

☆ Reprint requests: James E. Udelson, MD, Division of Cardiology, Tufts University School of Medicine, Boston, MA 02111.

PII: S0002-8703(01)46381-2

doi: 10.1067/mhj.2001.115584

American Heart Journal
Volume 141, Issue 6 , Pages 899-907 , June 2001

Article Tools

* Image Usage & Resolution